Resonance Health (ASX:RHT) ROE % Adjusted to Book Value: 13.54% (As of Dec. 2025)


What is Resonance Health ROE % Adjusted to Book Value?

Resonance Health ASX:RHT +4.55% ROE % Adjusted to Book Value is 13.54% as of Dec. 2025. The stock has 6 warning signs investors should review.

Resonance Health's ROE % for the quarter that ended in Dec. 2025 was 28.84%. Resonance Health's PB Ratio for the quarter that ended in Dec. 2025 was 2.13. Resonance Health's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 13.54%.

Resonance Health ROE % Adjusted to Book Value Related Terms

Resonance Health ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Resonance Health's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resonance Health ROE % Adjusted to Book Value Chart

Resonance Health Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 -4.23 -4.01 0.66 -8.74

Resonance Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.95 5.69 -8.37 -7.36 13.54

ASX:RHT vs VEEV, BTSG, TEM: ROE % Adjusted to Book Value Comparison

For the Health Information Services subindustry, Resonance Health's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resonance Health ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Resonance Health's ROE % Adjusted to Book Value falls into.


Resonance Health ROE % Adjusted to Book Value Calculation

Resonance Health's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-17.05% / 1.95
=-8.74%

Resonance Health's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=28.84% / 2.13
=13.54%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 13.54% mean?
Resonance Health (ASX:RHT) has a ROE % Adjusted to Book Value of 13.54% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Resonance Health and its competitors.
Is Resonance Health's ROE % Adjusted to Book Value too high?
Resonance Health's current ROE % Adjusted to Book Value is 13.54%.
How does Resonance Health's ROE % Adjusted to Book Value compare to VEEV and BTSG?
Resonance Health's ROE % Adjusted to Book Value of 13.54% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Resonance Health and its competitors. Resonance Health's current ROE % Adjusted to Book Value is 13.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current ROE % Adjusted to Book Value is 13.54%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current ROE % Adjusted to Book Value is 13.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resonance Health Business Description

Address 141 Burswood Road, Level 1, Burswood, Perth, WA, AUS, 6100
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.